CAS: 197509-46-9 - Laniquidar
Formula:C37H36N4O3
InChI:InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
InChI key:InChIKey=TULGGJGJQXESOO-UHFFFAOYSA-N
SMILES:O=C(OC)C1=CN=C2C(C=3C=CC=CC3CCN21)=C4CCN(CCC5=CC=C(OCC6=NC=7C=CC=CC7C=C6)C=C5)CC4
- Synonyms:
- 5H-Imidazo[2,1-b][3]benzazepine-3-carboxylic acid, 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-, methyl ester
- Laniquidar
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Laniquidar REF: 3D-XHA50946CAS: 197509-46-9 | Min. 95% | To inquire | Tue 07 Jan 25 |
 | Laniquidar REF: TM-T64133CAS: 197509-46-9 | - - - | 1,435.00 €~2,359.00 € | Mon 13 Jan 25 |
Laniquidar
CAS:197509-46-9
Laniquidar is a drug that is used in cancer chemotherapy. It is a substrate for …
Formula:
C37H36N4O3
Purity:
Min. 95%
Molecular weight:
584.7 g/mol
Ref: 3D-XHA50946
| 1mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Laniquidar
CAS:197509-46-9
Laniquidar (R101933) inhibits P-glycoprotein (IC50: 0.51 μM), poor oral bioavailability, modulates drug resistance transporters.
Formula:
C37H36N4O3
Color and Shape:
Solid
Molecular weight:
584.71
Ref: TM-T64133
| 25mg | 1,435.00 € | ||
| 50mg | 1,869.00 € | ||
| 100mg | 2,359.00 € |
Estimated delivery in United States, on Monday 13 Jan 2025
